Cargando…

Adolescent Male Human Papillomavirus Vaccination

Objective. To determine male vaccination rates with quadrivalent human papillomavirus vaccine (HPV4) before and after the October 2011 national recommendation to routinely immunize adolescent males. Methods. We reviewed HPV4 dose 1 (HPV4-1) uptake in 292 adolescent males in our urban clinic prior to...

Descripción completa

Detalles Bibliográficos
Autores principales: Nanagas, Vivian C., Stolfi, Adrienne, Nanagas, Maria T., Eberhart, Gregory M., Alter, Sherman J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905155/
https://www.ncbi.nlm.nih.gov/pubmed/27336012
http://dx.doi.org/10.1177/2333794X16642373
_version_ 1782437219160555520
author Nanagas, Vivian C.
Stolfi, Adrienne
Nanagas, Maria T.
Eberhart, Gregory M.
Alter, Sherman J.
author_facet Nanagas, Vivian C.
Stolfi, Adrienne
Nanagas, Maria T.
Eberhart, Gregory M.
Alter, Sherman J.
author_sort Nanagas, Vivian C.
collection PubMed
description Objective. To determine male vaccination rates with quadrivalent human papillomavirus vaccine (HPV4) before and after the October 2011 national recommendation to routinely immunize adolescent males. Methods. We reviewed HPV4 dose 1 (HPV4-1) uptake in 292 adolescent males in our urban clinic prior to national recommendations and followed-up for HPV4 series completion rates. After national recommendation, 248 urban clinic and 247 suburban clinic males were reviewed for HPV4-1 uptake. Factors associated with HPV4-1 refusal were determined with multiple logistic regression. Results. Of the initial 292 males, 78% received HPV4-1 and 38% received the 3-dose series. After recommendation, HPV4-1 uptake was 59% and 7% in urban and suburban clinics, respectively. Variables associated with HPV4-1 uptake/refusal included time period, race, type of insurance, and receipt of concurrent vaccines. Conclusions. HPV4-1 vaccination rates in our urban clinic were high before and after routine HPV vaccine recommendations for adolescent males. Our vaccination rates were much higher than in a suburban practice.
format Online
Article
Text
id pubmed-4905155
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-49051552016-06-22 Adolescent Male Human Papillomavirus Vaccination Nanagas, Vivian C. Stolfi, Adrienne Nanagas, Maria T. Eberhart, Gregory M. Alter, Sherman J. Glob Pediatr Health Original Article Objective. To determine male vaccination rates with quadrivalent human papillomavirus vaccine (HPV4) before and after the October 2011 national recommendation to routinely immunize adolescent males. Methods. We reviewed HPV4 dose 1 (HPV4-1) uptake in 292 adolescent males in our urban clinic prior to national recommendations and followed-up for HPV4 series completion rates. After national recommendation, 248 urban clinic and 247 suburban clinic males were reviewed for HPV4-1 uptake. Factors associated with HPV4-1 refusal were determined with multiple logistic regression. Results. Of the initial 292 males, 78% received HPV4-1 and 38% received the 3-dose series. After recommendation, HPV4-1 uptake was 59% and 7% in urban and suburban clinics, respectively. Variables associated with HPV4-1 uptake/refusal included time period, race, type of insurance, and receipt of concurrent vaccines. Conclusions. HPV4-1 vaccination rates in our urban clinic were high before and after routine HPV vaccine recommendations for adolescent males. Our vaccination rates were much higher than in a suburban practice. SAGE Publications 2016-04-26 /pmc/articles/PMC4905155/ /pubmed/27336012 http://dx.doi.org/10.1177/2333794X16642373 Text en © The Author(s) 2016 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Nanagas, Vivian C.
Stolfi, Adrienne
Nanagas, Maria T.
Eberhart, Gregory M.
Alter, Sherman J.
Adolescent Male Human Papillomavirus Vaccination
title Adolescent Male Human Papillomavirus Vaccination
title_full Adolescent Male Human Papillomavirus Vaccination
title_fullStr Adolescent Male Human Papillomavirus Vaccination
title_full_unstemmed Adolescent Male Human Papillomavirus Vaccination
title_short Adolescent Male Human Papillomavirus Vaccination
title_sort adolescent male human papillomavirus vaccination
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905155/
https://www.ncbi.nlm.nih.gov/pubmed/27336012
http://dx.doi.org/10.1177/2333794X16642373
work_keys_str_mv AT nanagasvivianc adolescentmalehumanpapillomavirusvaccination
AT stolfiadrienne adolescentmalehumanpapillomavirusvaccination
AT nanagasmariat adolescentmalehumanpapillomavirusvaccination
AT eberhartgregorym adolescentmalehumanpapillomavirusvaccination
AT altershermanj adolescentmalehumanpapillomavirusvaccination